<DOC>
	<DOCNO>NCT01263951</DOCNO>
	<brief_summary>The goal study determine effect combine everolimus sorafenib patient metastatic differentiated thyroid cancer progress sorafenib alone .</brief_summary>
	<brief_title>Study Everolimus Sorafenib Patients With Advanced Thyroid Cancer Who Progressed Sorafenib Alone</brief_title>
	<detailed_description>The purpose research study : 1 . Find sorafenib everolimus prevent growth tumor grow treated sorafenib alone 2 . Find long one might benefit treatment sorafenib everolimus 3 . Find side effect drug may cause 4 . Measure amount sorafenib everolimus blood see `` marker '' find help understand might benefit sorafenib everolimus .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis thyroid cancer , metastatic unresectable standard curative palliative measure exist longer effective . All patient require sorafenib entry document progression previous treatment sorafenib . Measurable disease define least one malignant lesion accurately measure computerized tomography ( CT ) and/or magnetic resonance imaging ( MRI ) scan . ECOG performance status &lt; 2 . Life expectancy great 3 month . Intellectual , emotional , physical ability comply oral medication . Restrictions regard certain prior treatment apply . Significant medical disease include : uncontrolled congestive heart failure ; active symptom coronary artery disease , uncontrolled seizure disorder ; active infection ; uncontrolled diabetes mellitus ; requirement chronic high dose corticosteroid treatment ( Topical inhale corticosteroid allow ) ; requirement concurrent immunosuppressive drug ( ) ; active autoimmune disease . Organ allografts . Known HIVinfection ( HIV test require participation ) . Pregnant breast feeding . Women childbearing potential sexually active male must advise take precaution prevent pregnancy treatment History second cancer ( except adequately treat basal cell squamous cell skin cancer , situ treated cervical cancer , colon cancer melanoma , cancer patient diseasefree three year ) . Known hypersensitivity everolimus rapamycins ( e.g. , sirolimus , temsirolimus ) excipients Use experimental therapy within 4 week prior baseline evaluation do prior enrollment ( exception sorafenib may continue treatment start ) . Therefore , experimental treatment sorafenib must discontinue 4 week prior baseline study enrollment . Patients previously tolerate sorafenib 200 mg daily exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Differentiated metastatic thyroid cancer</keyword>
</DOC>